Literature DB >> 2864949

Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias.

B Habibi.   

Abstract

Four individuals with anti-glafenine, anti-latamoxef and anti-teniposide antibodies were found to have an associated red blood cell autoantibody. The two components could be separated by selective absorption and showed distinct time course patterns. In three patients a well-defined blood group antigen was recognized as the receptor for both auto- and drug specific antibodies. Similarities between this type of immune response to drugs and the well-known hapten and carrier specificities developed in animals immunized by hapten-carrier conjugates are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864949     DOI: 10.1111/j.1365-2141.1985.tb04069.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies.

Authors:  F H Claas
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity.

Authors:  A Pereira; C Sanz; F Cervantes; R Castillo
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

3.  Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.

Authors:  Daniel W Bougie; Peter R Wilker; Richard H Aster
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

4.  No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials.

Authors:  Kamal Hamed; Tatiana Wiktorowicz; Maziar Assadi Gehr
Journal:  Infect Drug Resist       Date:  2020-09-16       Impact factor: 4.003

Review 5.  Haematological effects of non-narcotic analgesics.

Authors:  P A Miescher; W Pola
Journal:  Drugs       Date:  1986       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.